NeoDynamics gears up for US launch by partnering with Diligent

NeoDynamics announced today it is partnering with Diligent Health Solutions who will support the company for the upcoming launch of its novel pulse biopsy system NeoNavia.

“Now that we have clearance from the US Food and Drug Administration, we are ready to move quickly to start introducing the NeoNavia system to clinicians and potential partners in the US,” said Anna Eriksrud, CEO of NeoDynamics. “Teaming up with Diligent to start our sales effort is a key milestone for the company. The US breast biopsy market is expected to reach $830 million by 2025 so this is an exciting moment for the company’s future.”

Diligent will assist NeoDynamics in communicating with patients, caregivers, and health care professionals, from initial consultation to strategic implementation and daily operations.  Their specialists will support the company’s efforts to manage medical information, reimbursement and coding services.

“The entire leadership team of Diligent Health Solutions is excited to be supporting NeoDynamics for the US launch of its NeoNavia biopsy system. This innovative, ultrasound-guided system will be of significant value to people facing a breast cancer diagnosis as well as to their health care providers,” said Diligent’s Eva Mitchell, VP of Business Development.  

NeoNavia is an innovative biopsy system that uses a patented pulse technology for controlled and accurate needle insertion. It is based on research at the Karolinska Institutet in Stockholm. NeoDynamics’ goal is for the pulse technology to become the new standard for ultrasound-guided breast biopsies. The product has CE approval in Europe, where it is in clinical use.

For further information, please contact:

Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444 966 or e-mail anna.eriksrud@neodynamics.com

Aaron Wong, CFO NeoDynamics AB,  phone +46735 972 011 or e-mail aaron.wong@neodynamics.com

About NeoDynamics

NeoDynamics AB is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and will soon launch in the USA. NeoDynamic’s shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB.

About NeoNavia

NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumor whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.